Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study
- PMID: 26496954
- PMCID: PMC4620739
- DOI: 10.1186/s12879-015-1206-3
Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study
Abstract
Background: As the average age of the HIV-positive population increases, there is increasing need to monitor patients for the development of comorbidities as well as for drug toxicities.
Methods: We examined factors associated with the frequency of measurement of liver enzymes, renal function tests, and lipid levels among participants of the Canadian Observational Cohort (CANOC) collaboration which follows people who initiated HIV antiretroviral therapy in 2000 or later. We used zero-inflated negative binomial regression models to examine the associations of demographic and clinical characteristics with the rates of measurement during follow-up. Generalized estimating equations with a logit link were used to examine factors associated with gaps of 12 months or more between measurements.
Results: Electronic laboratory data were available for 3940 of 7718 CANOC participants. The median duration of electronic follow-up was 3.5 years. The median (interquartile) rates of tests per year were 2.76 (1.60, 3.73), 2.55 (1.44, 3.38) and 1.42 (0.50, 2.52) for liver, renal and lipid parameters, respectively. In multivariable zero-inflated negative binomial regression models, individuals infected through injection drug use (IDU) were significantly less likely to have any measurements. Among participants with at least one measurement, rates of measurement of liver, renal and lipid tests were significantly lower for younger individuals and Aboriginal Peoples. Hepatitis C co-infected individuals with a history of IDU had lower rates of measurement and were at greater risk of having 12 month gaps between measurements.
Conclusions: Hepatitis C co-infected participants infected through IDU were at increased risk of gaps in testing, despite publicly funded health care and increased risk of comorbid conditions. This should be taken into consideration in analyses examining factors associated with outcomes based on laboratory parameters.
Similar articles
-
Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history.AIDS. 2014 Jan 2;28(1):121-7. doi: 10.1097/QAD.0000000000000020. AIDS. 2014. PMID: 24413263
-
Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.BMC Infect Dis. 2017 Apr 4;17(1):246. doi: 10.1186/s12879-017-2350-8. BMC Infect Dis. 2017. PMID: 28376824 Free PMC article.
-
Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort.AIDS. 2006 Feb 14;20(3):323-31. doi: 10.1097/01.aids.0000198091.70325.f4. AIDS. 2006. PMID: 16439865
-
Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study.PLoS One. 2013 Dec 31;8(12):e83649. doi: 10.1371/journal.pone.0083649. eCollection 2013. PLoS One. 2013. PMID: 24391803 Free PMC article. Clinical Trial.
-
Effect of antiretroviral therapy and hepatitis c co-infection on changes in lipid levels in HIV-Infected patients 48 weeks after initiation of therapy.HIV Clin Trials. 2007 Nov-Dec;8(6):429-36. doi: 10.1310/hct0806-429. HIV Clin Trials. 2007. PMID: 18042508 Clinical Trial.
References
-
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultAndAdolescentGL.pdf AdolescentGL.pdf. Accessed 1 July 2013.
-
- The European AIDS Clinical Society (EACS) Guidelines Version 6.1–November 2012. The European AIDS Clinical Society. Available at: http://www.eacsociety.org/. Accessed 1 July 2013.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials